• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常白细胞和血液系统恶性肿瘤中的端粒酶活性。

Telomerase activity in normal leukocytes and in hematologic malignancies.

作者信息

Counter C M, Gupta J, Harley C B, Leber B, Bacchetti S

机构信息

Department of Pathology, McMaster University, Hamilton, Ontario, Canada.

出版信息

Blood. 1995 May 1;85(9):2315-20.

PMID:7727765
Abstract

Telomeres are essential for function and stability of eukaryotic chromosomes. In the absence of telomerase, the enzyme that synthesizes telomeric DNA, telomeres shorten with cell division, a process thought to contribute to cell senescence and the proliferative crisis of transformed cells. We reported telomere stabilization concomitant with detection of telomerase activity in cells immortalized in vitro and in ovarian carcinoma cells, and suggested that telomerase is essential for unlimited cell proliferation. We have now examined the temporal pattern of telomerase expression in selected hematologic malignancies. We found that, unlike other somatic tissues, peripheral, cord blood, and bone marrow leukocytes from normal donors expressed low levels of telomerase activity. In leukocytes from chronic lymphocytic leukemia (CLL) patients, activity was lower than in controls in early disease, and comparable with controls in late disease. Relative to bone marrow, telomerase activity was enhanced in myelodysplastic syndrome (MDS) and more significantly so in acute myeloid leukemia (AML). Regardless of telomerase levels, telomeres shortened with progression of the diseases. Our results suggest that early CLL and MDS cells lack an efficient mechanism of telomere maintenance and that telomerase is activated late in the progression of these cancers, presumably when critical telomere loss generates selective pressure for cell immortality.

摘要

端粒对于真核染色体的功能和稳定性至关重要。在缺乏合成端粒DNA的酶——端粒酶的情况下,端粒会随着细胞分裂而缩短,这一过程被认为与细胞衰老及转化细胞的增殖危机有关。我们报道了在体外永生化细胞和卵巢癌细胞中检测到端粒酶活性时伴随的端粒稳定现象,并提出端粒酶对于细胞的无限增殖至关重要。我们现在研究了特定血液系统恶性肿瘤中端粒酶表达的时间模式。我们发现,与其他体细胞组织不同,正常供体的外周血、脐带血和骨髓白细胞表达的端粒酶活性水平较低。在慢性淋巴细胞白血病(CLL)患者的白细胞中,疾病早期活性低于对照组,疾病晚期与对照组相当。相对于骨髓,骨髓增生异常综合征(MDS)中端粒酶活性增强,在急性髓系白血病(AML)中更为显著。无论端粒酶水平如何,端粒都会随着疾病进展而缩短。我们的结果表明,早期CLL和MDS细胞缺乏有效的端粒维持机制,并且端粒酶在这些癌症进展后期被激活,推测是在关键端粒丢失产生细胞永生的选择性压力时。

相似文献

1
Telomerase activity in normal leukocytes and in hematologic malignancies.正常白细胞和血液系统恶性肿瘤中的端粒酶活性。
Blood. 1995 May 1;85(9):2315-20.
2
Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.端粒稳定性在骨髓增生异常综合征高危患者群体中常常受损。
Clin Cancer Res. 1999 May;5(5):1155-60.
3
Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.使用端粒酶抑制剂BIBR1532对白血病细胞的选择性细胞毒性和端粒损伤
Blood. 2005 Feb 15;105(4):1742-9. doi: 10.1182/blood-2003-12-4322. Epub 2004 Oct 26.
4
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.急性和慢性白血病在体外培养前后的端粒酶活性和端粒长度
Cancer Res. 2000 Feb 1;60(3):610-7.
5
Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis.
Cancer Genet Cytogenet. 1997 Mar;94(1):67-72. doi: 10.1016/s0165-4608(96)00277-4.
6
Telomerase activity in human ovarian carcinoma.人卵巢癌中的端粒酶活性
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2900-4. doi: 10.1073/pnas.91.8.2900.
7
Telomerase activity in myelodysplastic syndromes.骨髓增生异常综合征中的端粒酶活性
Leuk Res. 2005 Oct;29(10):1131-9. doi: 10.1016/j.leukres.2005.03.006. Epub 2005 Apr 7.
8
Development of retinoblastoma in the absence of telomerase activity.在缺乏端粒酶活性的情况下视网膜母细胞瘤的发生。
J Natl Cancer Inst. 1996 Aug 21;88(16):1152-7. doi: 10.1093/jnci/88.16.1152.
9
Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.正常个体以及急性和慢性髓系白血病或骨髓增生异常综合征患者的骨髓单个核细胞产生基质金属蛋白酶的情况。
Clin Cancer Res. 1999 May;5(5):1115-24.
10
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.端粒功能障碍和融合在慢性淋巴细胞白血病进展过程中的作用:端粒危机的证据。
Blood. 2010 Sep 16;116(11):1899-907. doi: 10.1182/blood-2010-02-272104. Epub 2010 Jun 10.

引用本文的文献

1
High-Throughput Screening Tool to Identify Small Molecule Inhibitors of Telomerase.用于鉴定端粒酶小分子抑制剂的高通量筛选工具
ACS Chem Biol. 2025 Jul 18;20(7):1707-1714. doi: 10.1021/acschembio.5c00244. Epub 2025 Jun 10.
2
Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).间皮瘤中的端粒与端粒酶:病理生理学、生物标志物及新兴治疗策略(综述)
Int J Oncol. 2025 Mar;66(3). doi: 10.3892/ijo.2025.5729. Epub 2025 Feb 21.
3
A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches.
癌症与衰老中端粒损耗的综述:当前的分子见解及未来的治疗方法
Cancers (Basel). 2025 Jan 14;17(2):257. doi: 10.3390/cancers17020257.
4
A telomere-related gene risk model for predicting prognosis and treatment response in acute myeloid leukemia.一种用于预测急性髓系白血病预后和治疗反应的端粒相关基因风险模型。
Heliyon. 2024 May 22;10(11):e31705. doi: 10.1016/j.heliyon.2024.e31705. eCollection 2024 Jun 15.
5
Cell Immortality: Effective Techniques to Achieve and Investigate Its Applications and Challenges.细胞永生:实现及研究其应用与挑战的有效技术
Life (Basel). 2024 Mar 21;14(3):417. doi: 10.3390/life14030417.
6
Genetically determined telomere length as a risk factor for hematological malignancies: evidence from Mendelian randomization analysis.遗传决定的端粒长度作为血液系统恶性肿瘤的风险因素:来自孟德尔随机分析的证据。
Aging (Albany NY). 2024 Mar 6;16(5):4684-4698. doi: 10.18632/aging.205625.
7
Telomerase-targeted therapies in myeloid malignancies.靶向端粒酶治疗髓系恶性肿瘤。
Blood Adv. 2023 Aug 22;7(16):4302-4314. doi: 10.1182/bloodadvances.2023009903.
8
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.急性髓系白血病免疫治疗的前景:当前进展与挑战
Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023.
9
TERT Extra-Telomeric Roles: Antioxidant Activity and Mitochondrial Protection.TERT 端粒外作用:抗氧化活性和线粒体保护。
Int J Mol Sci. 2023 Feb 23;24(5):4450. doi: 10.3390/ijms24054450.
10
Analysis of TERT Isoforms across TCGA, GTEx and CCLE Datasets.跨TCGA、GTEx和CCLE数据集对端粒酶逆转录酶(TERT)亚型的分析。
Cancers (Basel). 2021 Apr 13;13(8):1853. doi: 10.3390/cancers13081853.